|
Coronary heart disease
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease.
|
30947598 |
2020 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Few studies have investigated the relationship between PCSK9 levels and the severity of coronary artery disease in patients with acute coronary syndrome; thus, we herein aimed to investigate this relationship in patients with non-ST-elevation myocardial infarction (NSTEMI) who underwent coronary angiography.
|
31206403 |
2020 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.
|
31020929 |
2019 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
|
30076455 |
2019 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
We conducted a comprehensive search of electronic databases, up to December 1, 2018, for all RCTs comparing PCSK9 inhibition to placebo or ezetimibe in patients with hypercholesterolemia or coronary artery disease receiving maximally tolerated statin for primary or secondary prevention of mortality and cardiovascular outcomes.
|
31679643 |
2019 |
|
Coronary heart disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in PCSK-9 gene invariably translates into lower levels of LDL, and decreased risk of developing coronary artery disease.
|
30953636 |
2019 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese.
|
29974199 |
2019 |
|
Coronary heart disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Soon after, studies uncovered the role of PCSK9 in the regulation of LDL-receptor recycling and identified loss-of-function variants of PCSK9 that were associated with low circulating levels of LDL cholesterol (LDL-C) and a reduced risk of coronary artery disease.
|
30420622 |
2019 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
|
31207358 |
2019 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
The addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab, to statin therapy produced incremental regression of atherosclerotic plaques and a collaborative prevention of cardiovascular events in patients with coronary artery disease.
|
31495548 |
2019 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus.
|
29103916 |
2019 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
|
29622600 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to characterize the alterations in the lipidome of plasma and lipoprotein particles after administration of PCSK9 inhibiting antibody to patients with established coronary heart disease.
|
29366988 |
2018 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
While exposing the polygenic architecture of circulating lipids and the underpinnings of dyslipidaemia, these genome-wide association studies (GWAS) have provided further evidence of the critical role that lipids play in coronary heart disease (CHD) risk, as indicated by the 2.7-fold enrichment for macrophage gene expression in atherosclerotic plaques and the association of 25 loci (such as PCSK9, APOB, ABCG5-G8, KCNK5, LPL, HMGCR, NPC1L1, CETP, TRIB1, ABO, PMAIP1-MC4R, and LDLR) with CHD.
|
29800275 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
A state transition Markov model was developed to model the cost-effectiveness of PCSK9 inhibitors for prevention of coronary heart disease, ischaemic strokes, and death among high-risk patient subpopulations in Norway, in both primary and secondary settings.
|
28444187 |
2018 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 has emerged as a target for lipid-lowering therapy, but the predictive value of the serum level of PCSK9 for the severity of coronary disease is largely unknown.
|
29885102 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
The aim of this review is to summarize the recent major advances in cardiovascular pharmacotherapy, with a focus on (1) the new approved drug for treatment of heart failure with reduced ejection fraction-sacubitril/valsartan; (2) proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; (3) the novel reversal agents for non-vitamin K oral anticoagulants (NOACs); and finally, (4) new evidence on pharmacological treatment of coronary artery disease.
|
29589064 |
2018 |
|
Coronary heart disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 has emerged as a target for lipid-lowering therapy, but the predictive value of the serum level of PCSK9 for the severity of coronary disease is largely unknown.
|
30112872 |
2018 |
|
Coronary heart disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The association of genetically predicted Lp(a) concentration with CHD risk appeared to be independent of changes in LDL-C level owing to genetic variants that mimic the relationship of statins, PCSK9 inhibitors, and ezetimibe with CHD risk.
|
29926099 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Background Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to be related to several risk factors and diseases such as inflammatory markers and coronary artery disease.
|
28166668 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mature PCSK9 associated with atheroma volume and impaired vessel remodeling in HeFH patients with coronary artery disease.
|
28502498 |
2018 |
|
Coronary heart disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median of the population distribution of LDL-C-lowering alleles at 58 independent genomic regions, HMGCR, NPC1L1, or PCSK9.
|
30326043 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Using MR (Mendelian Randomization), we detected significant causal effects of circulating PCSK9 on coronary artery disease status and severity, carotid plaques, and intima-media thickness.
|
29748315 |
2018 |
|
Coronary heart disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
By contrast, similar proportional reductions in risks of IS and CHD have been observed in randomized trials of therapeutic PCSK9-inhibition.
|
29020353 |
2018 |
|
Coronary heart disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Those with variants leading to reduced PCSK9 have lower LDL-cholesterol levels and a reduced risk of coronary heart disease, and this has led to the development of various strategies aimed at reducing circulating PCSK9.
|
28025677 |
2017 |